Plus Therapeutics Announces Patient-Focused Presentation Supporting Brain Tumor Awareness Month

Principal Investigator Dr. Andrew Brenner to Lead Musella Foundation Live Webinar:
“A Promising New Radiotherapy for Recurrent Glioblastoma”

AUSTIN, Texas, May 12, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Dr. Andrew Brenner, development leader of an innovative drug portfolio platform that the company has recently licensed, is scheduled to conduct a live patient-focused webinar entitled, "A Promising New Radiotherapy for Recurrent Glioblastoma: An Introduction", on Sunday, May 17, 2020, at 7 pm EDT.

The event, part of the Musella Foundation Webinar Series, is to be presented live on the Foundation’s website at virtualtrials.com/webinar/ through a Zoom room.  If there is overflow, the webinar may also be streamed live on Facebook at facebook.com/Braintumor.  Participants are asked to join the digital room 5 minutes before the event and may ask questions live or email questions in advance to [e-mail].  There is no charge for the event, although the Foundation welcomes donations.

Plus Therapeutics is participating in the presentation as part of its recognition of Brain Tumor Awareness Month.  Every May, a number of events and activities take place across the nation to raise awareness of the fight against brain tumors.

On March 30, 2020, Plus Therapeutics announced that it had entered into a definitive agreement to license the radiolabeled nanoliposome drug portfolio platform developed by a multi-institutional consortium based in Texas at the Mays Cancer Center / UT Health San Antonio MD Anderson Cancer Center led by Dr. Andrew Brenner, MD, PhD.  Dr. Brenner is the Kolitz Chair in Neuro-Oncology Research and Co-Leader of the Experimental and Developmental Therapeutics Program.

The platform is anchored around nanoliposome-encapsulated radionuclides for several cancer targets. The lead drug asset is a chelated Rhenium NanoLiposome (RNL), initially being developed for recurrent glioblastoma.  RNL is infused directly into the brain tumor via precision brain mapping and convection enhanced delivery technology to deliver very high therapeutic doses of radiation to patients whose cancer has recurred following initial surgical resection and treatment with chemotherapy and radiation.